May 18 2007, 2:00 PM EST
News source: Business Wire
Research and Markets (http://www.researchandmarkets.com/reports/c31925) has announced the addition of the Espicom Business Intelligence Ltd report: Apotex Generics Company Intelligence Report to their offering
Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the companys active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Topics Covered Executive Summary Introduction Products Apotex ANDA Approvals, 2002-06 Novex Pharma ANDA Approvals, 2002-05 TorPharm ANDA Approvals, 2002-05 Plavix (clopidogrel) Bristol-Myers Squibb and sanofi-aventis respond. Court orders Apotex to halt sales of clopidogrel Recent product approvals Diltiazem hydrochloride Clopidogrel Zonisamide Ofloxacin otic Leflunomide tablets Fosinopril Haloperidol Desmopressin acetate nasal spray Financial results Cangene Cangene Financial Results, 2000-05 (C$000s) Major developments Apotex opens new R&D facility, expands other plants Mergers, acquisitions and agreements Akorn and Apotex sign ophthalmics agreement. Orchid Chemicals & Pharmaceuticals BioGeneriX Litigation Unigene/Upsher-Smith file patent infringement lawsuit against Apotex. Allergan wins Acular patent infringement lawsuit Amlodipine Court favours Alpharmas gabapentin exclusivity Contact Details
Summary
Apotex Inc. is the largest Canadian-owned pharmaceutical company. Founded with two employees in 1974, it now employs over 6,000 people; 5,300 of them are based in Canada, and the company has over 1,800 scientific staff. With a number of subsidiaries in Canada, Apotex is also active in around 115 countries, including subsidiaries, joint ventures or licensing agreements in Asia, Europe and Latin America. Products are sold under the Apotex brand, and under customer brand names.
API manufacturing is largely done at Apotex Pharmachem, formerly known as Brantford Chemicals.
In 2006, Apotex received eleven ANDA approvals, including one for clopidogrel bisulphate, the generic form of sanofi-aventis' Plavix. In a lucrative but controversial and potentially very risky move, Apotex launched its version in August 2006 without waiting for the attendant legal issues to be resolved.
Through Cangene, Apotex is active in the biosimilar area. One product, Leucotropin, is under review in Canada, while the company has plans to submit a human growth hormone product in the USA soon. Cangene signed an agreement with BioGeneriX, a subsidiary of ratiopharm, in 2003.
Companies Mentioned
-- Akorn
-- Orchid Chemicals & Pharmaceuticals
-- BioGeneriX
For more information visit http://www.researchandmarkets.com/reports/c31925
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All